Pharmacogenetics of MicroRNAs and MicroRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  López López, Elixabet ^a   Gutiérrez Camino, Ángela ^a   Piñán, Maria Ángeles ^b   Sánchez Toledo, José ^c   Uriz, Jose Javier ^d   Ballesteros, Javier ^a   García Miguel, Purificación ^e   Navajas, Aurora ^b   García Orad, África ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL DONOSTIA   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; MERCAPTOPURINE; METHOTREXATE; MICRORNA; MICRORNA 1206; MICRORNA 1307; MICRORNA 146A; MICRORNA 2053; MICRORNA 423; MICRORNA 453; MICRORNA 618; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHILD; CONSOLIDATION CHEMOTHERAPY; DIARRHEA; DROSHA GENE; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; GENE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERBILIRUBINEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; PHARMACOGENETICS; RNA PROCESSING; SINGLE NUCLEOTIDE POLYMORPHISM; VOMITING; BIOSYNTHESIS; GENETICS; GENOTYPING TECHNIQUE; METABOLISM; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; FEMALE; GENOTYPING TECHNIQUES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MICRORNAS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RNA PROCESSING, POST-TRANSCRIPTIONAL;

EID: 84897480230     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091261     Document Type: Article

References (29)

1. Johnston WT, Lightfoot TJ, Simpson J, Roman E (2010) Childhood cancer survival: a report from the United Kingdom Childhood Cancer Study. Cancer Epidemiol 34: 659-666.
2. Pui CH, Robison LL, Look AT (2008) Acute lymphoblastic leukaemia. Lancet 371: 1030-1043. (Pubitemid 351389536)
3. Pui CH, Mullighan CG, Evans WE, Relling MV (2012) Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 120: 1165-1174.
4. Kishi S, Cheng C, French D, Pei D, Das S, et al. (2007) Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 109: 4151-4157. (Pubitemid 46743376)
5. Huang L, Tissing WJ, de Jonge R, van Zelst BD, Pieters R (2008) Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia 22: 1798-1800.
6. Liu SG, Li ZG, Cui L, Gao C, Li WJ, et al. (2011) Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population. Leuk Lymphoma 52: 1030-1040.
7. Treviño LR, Shimasaki N, Yang W, Panetta JC, Cheng C, et al. (2009) Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 27: 5972-5978.
8. Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Piñan MA, Garcia-Miguel P, et al. (2011) Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 57: 612-619.
9. Faganel Kotnik B, Grabnar I, Bohanec Grabar P, Dolzan V, Jazbec J (2011) Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol 67: 993-1006.
10. Wan Rosalina WR, Teh LK, Mohamad N, Nasir A, Yusoff R, et al. (2012) Polymorphism of ITPA 94C. A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine. J Clin Pharm Ther 37: 237-241.
11. Gong J, Tong Y, Zhang HM, Wang K, Hu T, et al. (2012) Genome-wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis. Hum Mutat 33: 254-263.
12. Ryan BM, Robles AI, Harris CC (2010) Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 10: 389-402.
13. Munker R, Calin GA (2011) MicroRNA profiling in cancer. Clin Sci (Lond) 121: 141-158.
14. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB (2003) Prediction of mammalian microRNA targets. Cell 115: 787-798. (Pubitemid 38058492)
15. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
16. Yokoi T, Nakajima M (2013) microRNAs as mediators of drug toxicity. Annu Rev Pharmacol Toxicol 53: 377-400.
17. Schotte D, De Menezes RX, Moqadam FA, Khankahdani LM, Lange-Turenhout E, et al. (2011) MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica 96: 703-711.
18. Han BW, Feng DD, Li ZG, Luo XQ, Zhang H, et al. (2011) A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. Hum Mol Genet 20: 4903-4915.
19. Slaby O, Bienertova-Vasku J, Svoboda M, Vyzula R (2012) Genetic polymorphisms and microRNAs: new direction in molecular epidemiology of solid cancer. J Cell Mol Med 16: 8-21.
20. Mishra PJ, Bertino JR (2009) MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 10: 399-416.
21. Mishra PJ, Humeniuk R, Longo-Sorbello GS, Banerjee D, Bertino JR (2007) A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci USA 104: 13513-13518. (Pubitemid 47293976)
22. Lopez-Lopez E, Ballesteros J, Piñan MA, Sanchez de Toledo J, Garcia de Andoin N, et al. (2013) Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics 23: 53-61.
23. Hiard S, Charlier C, Coppieters W, Georges M, Baurain D (2010) Patrocles: a database of polymorphic miRNA-mediated gene regulation in vertebrates. Nucleic Acids Res 38: D640-651.
24. Bao L, Zhou M, Wu L, Lu L, Goldowitz D, et al. (2007) PolymiRTS Database: linking polymorphisms in microRNA target sites with complex traits. Nucleic Acids Res 35: D51-54. (Pubitemid 46056169)
25. Ziebarth JD, Bhattacharya A, Chen A, Cui Y (2012) PolymiRTS Database 2.0: linking polymorphisms in microRNA target sites with human diseases and complex traits. Nucleic Acids Res 40: D216-221.
26. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing.: J Royal Stat Soc Series B.
27. Zhang X, Yang H, Lee JJ, Kim E, Lippman SM, et al. (2010) MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. Carcinogenesis 31: 2118-2123.
28. Rotunno M, Zhao Y, Bergen AW, Koshiol J, Burdette L, et al. (2010) Inherited polymorphisms in the RNA-mediated interference machinery affect microRNA expression and lung cancer survival. Br J Cancer 103: 1870-1874.
29. Phua SL, Sivakamasundari V, Shao Y, Cai X, Zhang LF, et al. (2011) Nuclear accumulation of an uncapped RNA produced by Drosha cleavage of a transcript encoding miR-10b and HOXD4. PLoS One 6: e25689.